统计剂使用与随着时间的推移肌肉功能和质量下降有关,无论统计剂的药物基因组分数如何
Mélissa Gentreau1, Mahitab Sakr1, Salahuddin Mohammad1
1Functional Pharmacology and Neuroscience, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Journal of cachexia, sarcopenia and muscle
|November 21, 2025
概括
静止剂的使用与随着时间的推移肌肉力量和质量下降有关,无论遗传因素如何. 对服用他类药物的人来说,监测肌肉健康至关重要,以保持整体健康.
科学领域:
- 心血管健康 心血管健康
- 药物基因组学 药物基因组学
- 肌肉骨健康 肌肉骨健康
背景情况:
- 类药物广泛用于预防心血管疾病.
- 对于他类药物对骨肌肉功能和质量的潜在不良影响尚未完全理解.
研究的目的:
- 调查他类药物使用与肌肉功能和肌肉质量之间的关联.
- 为了确定药物基因组评分 (PGS) 是否会改变这些关联.
主要方法:
- 对297,977名英国生物库参与者的分析.
- 测量了握力和尾肌肉量 (ALM).
- 线性回归评估了截面和纵向关联,对共变量进行调整,并测试了PGS相互作用.
主要成果:
- 立方体使用与较低的基线握力和ALM相关.
- 持续使用他类药物加快了随着时间的推移,握力和ALM的下降.
- PGS并没有显著改变肌肉功能或质量下降的速度.
结论:
- 持续使用他类药物与肌肉功能和质量减少有关,不论遗传敏感性如何.
- 监测他类药物使用者的肌肉骨健康是很重要的.
- 支持进一步研究饮食和运动以保持肌肉功能.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
186
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
186
Atherosclerosis III: Management
301
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
301
Disorders of the Skeletal Muscle
1.7K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.7K
Skeletal Muscle Relaxants: Adverse Effects
763
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
763
Cross-bridge Cycle
122.0K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
122.0K


